Background: Age-appropriate vaccination is one of the key public health measures to prevent morbidity and mortality worldwide. Despite its importance, there has been insufficient emphasis on tackling this problem. Therefore, this study aimed to determine the prevalence of age-appropriate vaccination and  associated factors in Ethiopia. Method: Data of 1077 children aged 12-35months were extracted from the Ethiopian Mini Demographic and Health Survey 2019 using a prepared data extraction checklist and included in the analysis. The extracted data was analyzed using STATA version 14.0. Descriptive and inferential statistics were applied. then analysis at different levels was done using multilevel logistic regression. Significant variables were identified at p-value < 0.05 within 95% confidence level and AOR. Result: The pooled prevalence of age-appropriate vaccination in this study was 21.17% at 95%CI (18.73-23.61). Factors like mothers aged >= 40 (AOR=4.05 at 95%CI1.03, 15.83), 35-39 years (AOR= 4.62 at 95%CI1.27,16.71), 25-29 years, (AOR =4.07 at 95%CI 1.18,14.03), Maternal secondary education (AOR=1.85 at 95% CI 1.06, 3.22), Maternal primary education (AOR= 1.60 at 95% CI1.07, 2.41) and rural residence (AOR=0.34, 95%CI 0.23,0.51) were significant predictors of age-appropriate vaccinations. Conclusion:This study concluded that the prevalence of age-appropriate vaccination of children in Ethiopia is below the desired level. Hence, the stakeholders should give due attention to the timely vaccination of children equally as the effort being made to increase the coverage.

The authors have declared no competing interest.

The author(s) received no specific funding for this work.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Not Applicable

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

For the data we requested www.DHSmeasure.org, to obtain permission to access the data set from https://www.dhsprogram.com/data/available-datasets.cfm by submitting abstract. The DHS public-use datasets are protected from identification of respondents, households, or sample communities by procedures approved by the Institution Review Board. The data files do not contain household addresses or names of individuals. The data set was not used for other purposes except for the intended objective.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Not Applicable

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Not Applicable

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Not Applicable

The data used for this study is included within the article itself